Compare BRC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRC | CNTA |
|---|---|---|
| Founded | 1914 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2005 | 2021 |
| Metric | BRC | CNTA |
|---|---|---|
| Price | $83.31 | $39.64 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $1.20 | ★ $42.00 |
| AVG Volume (30 Days) | 170.4K | ★ 4.2M |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,144,698,000.00 | $15,000,000.00 |
| Revenue This Year | $7.36 | N/A |
| Revenue Next Year | $3.57 | N/A |
| P/E Ratio | $23.35 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $65.76 | $10.95 |
| 52 Week High | $99.29 | $40.26 |
| Indicator | BRC | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 76.90 |
| Support Level | $76.10 | $24.80 |
| Resistance Level | $86.37 | $40.26 |
| Average True Range (ATR) | 2.21 | 1.07 |
| MACD | 0.40 | 0.80 |
| Stochastic Oscillator | 73.80 | 96.49 |
Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.